相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Ian M. Silverman et al.
CANCER DISCOVERY (2021)
FGFR-TKI resistance in cancer: current status and perspectives
Sitong Yue et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor
Liangxing Wu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Dissecting the Role of the FGF19-FGFR4 Signaling Pathway in Cancer Development and Progression
Yanan Liu et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4
Robin A. Fairhurst et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma
Renata Rezende Miranda et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT
Molly R. Ryan et al.
MOLECULAR CANCER RESEARCH (2019)
FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR
Lei Li et al.
BMC CANCER (2019)
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma
Lipika Goyal et al.
CANCER DISCOVERY (2017)
1,3,5-Triazines: A promising scaffold for anticancer drugs development
Stella Cascioferro et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion
Sun Young Kim et al.
ONCOTARGET (2017)
Advances and challenges in targeting FGFR signalling in cancer
Irina S. Babina et al.
NATURE REVIEWS CANCER (2017)
KinMap: a web-based tool for interactive navigation through human kinome data
Sameh Eid et al.
BMC BIOINFORMATICS (2017)
Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer
Mai Tomiguchi et al.
CANCER SCIENCE (2016)
Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer
Wells S. Brown et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
Magda Bahcall et al.
CANCER DISCOVERY (2016)
Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use
Harshnira Patani et al.
ONCOTARGET (2016)
Illuminating the Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance for the FGFR1 Gatekeeper Mutation: The Achilles' Heel of Targeted Therapy
Christal D. Sohl et al.
ACS CHEMICAL BIOLOGY (2015)
Targeting FGFR Signaling in Cancer
Mehdi Touat et al.
CLINICAL CANCER RESEARCH (2015)
Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations
Leandro H. Gallo et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2015)
The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study
Camille Couffignal et al.
UROLOGY (2015)
Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor beta 1 signaling in metastatic breast cancers
Michael K. Wendt et al.
BREAST CANCER RESEARCH (2014)
Activating Mutations Cluster in the Molecular Brake Regions of Protein Kinases and Do Not Associate with Conserved or Catalytic Residues
Miguel A. Molina-Vila et al.
HUMAN MUTATION (2014)
The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor
Yoshito Nakanishi et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
Robert J. Motzer et al.
LANCET ONCOLOGY (2014)
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
Li Tan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
Liang Xie et al.
CLINICAL CANCER RESEARCH (2013)
Pseudo-Cyclization through Intramolecular Hydrogen Bond Enables Discovery of Pyridine Substituted Pyrimidines as New Mer Kinase Inhibitors
Weihe Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance
V. Chell et al.
ONCOGENE (2013)
Structural Mimicry of A-Loop Tyrosine Phosphorylation by a Pathogenic FGF Receptor 3 Mutation
Zhifeng Huang et al.
STRUCTURE (2013)
The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors
Sara A. Byron et al.
NEOPLASIA (2013)
AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
Paul R. Gavine et al.
CANCER RESEARCH (2012)
Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer
A. Nigel Brooks et al.
CLINICAL CANCER RESEARCH (2012)
Potent and Selective Aminopyrimidine-Based B-Raf Inhibitors with Favorable Physicochemical and Pharmacokinetic Properties
Simon Mathieu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
FGFR1 Amplification in Squamous Cell Carcinoma of The Lung
Rebecca S. Heist et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Martin Peifer et al.
NATURE GENETICS (2012)
Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening
Eric T. Sawey et al.
CANCER CELL (2011)
Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer
Y. Dodurga et al.
GENETICS AND MOLECULAR RESEARCH (2011)
Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase
Vito Guagnano et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
A Medicinal Chemist's Guide to Molecular Interactions
Caterina Bissantz et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Jonathan Weiss et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Entry into a new class of protein kinase inhibitors by pseudo ring design
Pascal Furet et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Activation of tyrosine kinases by mutation of the gatekeeper threonine
Mohammad Azam et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2008)
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Amit Dutt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases
Huaibin Chen et al.
MOLECULAR CELL (2007)
A molecular study of the t(4;14) in multiple myeloma
K Sibley et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
分享论文
